Hypofractionated external-beam radiotherapy for prostate cancer.

about

Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.

P2860

Q37578562-E5713AF3-59DF-4036-A6BF-32BC05C0D48C Q37702326-800C5B09-09EE-4333-9A71-27441FADDDFF

P2860

Hypofractionated external-beam radiotherapy for prostate cancer.

Item

http://www.wikidata.org/entity/Q36711751

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Hypofractionated external-beam radiotherapy for prostate cancer.

@ast

Hypofractionated external-beam radiotherapy for prostate cancer.

@en

type

Item

label

Hypofractionated external-beam radiotherapy for prostate cancer.

@ast

Hypofractionated external-beam radiotherapy for prostate cancer.

@en

prefLabel

Hypofractionated external-beam radiotherapy for prostate cancer.

@ast

Hypofractionated external-beam radiotherapy for prostate cancer.

@en

P1476

Hypofractionated external-beam radiotherapy for prostate cancer.

@en

P2093

Brian Kavanagh

http://www.w3.org/2001/XMLSchema#string

L Chinsoo Cho

http://www.w3.org/2001/XMLSchema#string

Robert Timmerman

http://www.w3.org/2001/XMLSchema#string

P2860

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.

Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding.

Stereotactic body radiotherapy for organ-confined prostate cancer.

Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

Is alpha/beta for prostate tumors really low?

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial

The expanding roles of stereotactic body radiation therapy and oligofractionation: toward a new practice of radiotherapy.

P304

103547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/103547

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236085314

http://www.w3.org/2001/XMLSchema#string

P698

23533777

http://www.w3.org/2001/XMLSchema#string

P932

3606774

http://www.w3.org/2001/XMLSchema#string

Hypofractionated external-beam radiotherapy for prostate cancer.

about

P2860

P2860

Hypofractionated external-beam radiotherapy for prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932